Allosteric modulation of G protein-coupled receptors.
暂无分享,去创建一个
Arthur Christopoulos | Patrick M Sexton | P. Sexton | A. Christopoulos | L. May | K. Leach | Katie Leach | Lauren T May
[1] P. Conn,et al. A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators , 2006, Molecular Pharmacology.
[2] K. Mohr,et al. Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity , 2006, Molecular Pharmacology.
[3] Anandan Palani,et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. , 2006, Virology.
[4] Yasushi Tojo,et al. Structural and Molecular Interactions of CCR5 Inhibitors with CCR5* , 2006, Journal of Biological Chemistry.
[5] M. Parmentier,et al. Allosteric Modulation of Binding Properties between Units of Chemokine Receptor Homo- and Hetero-Oligomers , 2006, Molecular Pharmacology.
[6] L. Sterin‐Borda,et al. Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients , 2006, Neuropharmacology.
[7] Lila M Gierasch,et al. The changing landscape of protein allostery. , 2006, Current opinion in structural biology.
[8] K. Neve,et al. Identification of a Zn2+-binding site on the dopamine D2 receptor. , 2006, Biochemical and biophysical research communications.
[9] U. Holzgrabe,et al. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. , 2006, Journal of medicinal chemistry.
[10] Andreas Mühlemann,et al. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. , 2006, European journal of pharmacology.
[11] C. Langmead,et al. Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist , 2006, Molecular Pharmacology.
[12] T. Schwartz,et al. Ago-Allosteric Modulation and Other Types of Allostery in Dimeric 7TM Receptors , 2006, Journal of receptor and signal transduction research.
[13] P. Sexton,et al. GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.
[14] J. Cryan,et al. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] H. Niznik,et al. Modulation of Agonist Binding to Human Dopamine Receptor Subtypes by l-Prolyl-l-leucyl-glycinamide and a Peptidomimetic Analog , 2005, Journal of Pharmacology and Experimental Therapeutics.
[16] U. Holzgrabe,et al. Atypical Muscarinic Allosteric Modulation: Cooperativity between Modulators and Their Atypical Binding Topology in Muscarinic M2 and M2/M5 Chimeric Receptors , 2005, Molecular Pharmacology.
[17] T. Kenakin. New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.
[18] F. Ehlert. Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.
[19] A. Christopoulos,et al. Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.
[20] A. IJzerman,et al. Allosteric modulators affect the internalization of human adenosine A1 receptors. , 2005, European journal of pharmacology.
[21] T. Schwartz,et al. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. , 2005, Molecular Endocrinology.
[22] Xi-Ping Huang,et al. Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide , 2005, Molecular Pharmacology.
[23] T. Durroux. Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. , 2005, Trends in pharmacological sciences.
[24] C. Goudet,et al. Allosteric functioning of dimeric class C G‐protein‐coupled receptors , 2005, The FEBS journal.
[25] S. Swillens,et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity , 2005, The EMBO journal.
[26] R. Abagyan,et al. Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes* , 2005, Molecular & Cellular Proteomics.
[27] T. Kenakin,et al. The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.
[28] C. Lindsley,et al. A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models , 2005, Journal of Pharmacology and Experimental Therapeutics.
[29] S. Hoare,et al. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.
[30] P. Sexton,et al. Regulation of M2 Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators , 2005, Journal of Pharmacology and Experimental Therapeutics.
[31] Johan Hoebeke,et al. Modulation of the M2 Muscarinic Acetylcholine Receptor Activity with Monoclonal Anti-M2 Receptor Antibody Fragments* , 2004, Journal of Biological Chemistry.
[32] A. Christopoulos,et al. Effects of anandamide on the binding and signaling properties of M1 muscarinic acetylcholine receptors. , 2004, Biochemical pharmacology.
[33] J. Wells,et al. Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.
[34] J. Banères,et al. Cooperative Conformational Changes in a G-protein-coupled Receptor Dimer, the Leukotriene B4 Receptor BLT1* , 2004, Journal of Biological Chemistry.
[35] D. A. Annis,et al. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. , 2004, Journal of the American Chemical Society.
[36] D. S. Hage,et al. Quantitative analysis of allosteric drug-protein binding by biointeraction chromatography , 2004, Nature Biotechnology.
[37] H. Mitsuya,et al. Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro , 2004, Journal of Virology.
[38] Terry Kenakin,et al. Allosteric modulators: the new generation of receptor antagonist. , 2004, Molecular interventions.
[39] Irina D Pogozheva,et al. Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. , 2004, Biochemistry.
[40] L. Prézeau,et al. The Heptahelical Domain of GABAB2 Is Activated Directly by CGP7930, a Positive Allosteric Modulator of the GABAB Receptor* , 2004, Journal of Biological Chemistry.
[41] P. Sexton,et al. Allosteric modulation of G protein-coupled receptors. , 2004, Current pharmaceutical design.
[42] P. Sexton,et al. Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[43] A. Christopoulos,et al. Investigation of the Interaction of a Putative Allosteric Modulator, N-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) Methanamine Hydrobromide (SCH-202676), with M1 Muscarinic Acetylcholine Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[44] M. Shlesinger,et al. Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators. , 2004, Biophysical journal.
[45] R. Wolf,et al. Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site* , 2004, Journal of Biological Chemistry.
[46] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[47] S. Urwyler,et al. Selected amino acids, dipeptides and arylalkylamine derivatives do not act as allosteric modulators at GABAB receptors. , 2004, European journal of pharmacology.
[48] E. Borda,et al. Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren's syndrome , 1996, Molecular and Cellular Biochemistry.
[49] S. Lazareno,et al. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. , 2004, Molecular pharmacology.
[50] Francine Acher,et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[51] D. Rognan,et al. Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor* , 2003, Journal of Biological Chemistry.
[52] J. Linden,et al. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. , 2003, Molecular pharmacology.
[53] Arthur Christopoulos,et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.
[54] S. Urwyler,et al. N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and Structurally Related Compounds: Novel Allosteric Enhancers of γ-Aminobutyric AcidB Receptor Function , 2003, Journal of Pharmacology and Experimental Therapeutics.
[55] L. Bristow,et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. , 2003, Molecular pharmacology.
[56] Philippe Billiald,et al. scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the β2-Adrenergic Receptor* , 2003, Journal of Biological Chemistry.
[57] E. Clercq. The bicyclam AMD3100 story , 2003, Nature Reviews Drug Discovery.
[58] John Ellis,et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. , 2003, Molecular pharmacology.
[59] M. Shlesinger,et al. Cellular and Behavioral Effects of D2 Dopamine Receptor Hydrophobic Eigenmode-Targeted Peptide Ligands , 2003, Neuropsychopharmacology.
[60] Claudio N. Cavasotto,et al. Structure‐based identification of binding sites, native ligands and potential inhibitors for G‐protein coupled receptors , 2003, Proteins.
[61] Xavier Langlois,et al. [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. , 2003, Molecular pharmacology.
[62] Thomas P. Sakmar,et al. Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry , 2003, Journal of Virology.
[63] Kenneth A Jacobson,et al. Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. , 2003, Molecular pharmacology.
[64] J. Kew,et al. Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.
[65] N. Ling,et al. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. , 2003, Molecular Pharmacology.
[66] B. Kobilka,et al. Identification of an Allosteric Binding Site for Zn2+on the β2 Adrenergic Receptor* , 2003, The Journal of Biological Chemistry.
[67] T. Schwartz,et al. Metal Ion-mediated Agonism and Agonist Enhancement in Melanocortin MC1 and MC4 Receptors* , 2002, The Journal of Biological Chemistry.
[68] S. Lazareno,et al. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. , 2002, Molecular pharmacology.
[69] K. Jacobson,et al. Identification of Acidic Residues in the Extracellular Loops of the Seven-transmembrane Domain of the Human Ca2+ Receptor Critical for Response to Ca2+ and a Positive Allosteric Modulator* , 2002, The Journal of Biological Chemistry.
[70] S. Foord. Receptor classification: post genome. , 2002, Current opinion in pharmacology.
[71] U. Hacksell,et al. Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.
[72] T. Kenakin,et al. G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.
[73] W. Sadee,et al. Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. , 2002, The Journal of pharmacology and experimental therapeutics.
[74] J. Longmore,et al. Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists* 210 , 2002, The Journal of Biological Chemistry.
[75] L. Limbird,et al. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. , 2002, Cellular signalling.
[76] L. Tong,et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.
[77] A. Christopoulos. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.
[78] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[79] S. Rees,et al. GPCR drug discovery through the exploitation of allosteric drug binding sites. , 2002, Receptors & channels.
[80] K. Mohr,et al. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. , 2002, Molecular pharmacology.
[81] S. Urwyler,et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. , 2001, Molecular pharmacology.
[82] K. Jacobson,et al. Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. , 2001, Molecular pharmacology.
[83] J. Kemp,et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[84] A. Krejci,et al. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. , 2001, Molecular pharmacology.
[85] J. Gleason,et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. , 2001, The Journal of pharmacology and experimental therapeutics.
[86] E. De Clercq,et al. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. , 2001, Molecular pharmacology.
[87] J. Adelman,et al. ATP-dependent Activation of the Intermediate Conductance, Ca2+-activated K+ Channel, hIK1, Is Conferred by a C-terminal Domain* , 2001, The Journal of Biological Chemistry.
[88] Michel Bouvier,et al. Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.
[89] D. Sibley,et al. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. , 2001, The Journal of pharmacology and experimental therapeutics.
[90] A. IJzerman,et al. Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. , 2001, Biochemical pharmacology.
[91] F. Fahrenholz,et al. Molecular modelling study of the role of cholesterol in the stimulation of the oxytocin receptor. , 2001, Acta biochimica Polonica.
[92] D. Hall,et al. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. , 2000, Molecular pharmacology.
[93] F. Gasparini,et al. The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.
[94] E. Freire,et al. Can allosteric regulation be predicted from structure? , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[95] S. Lazareno,et al. Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. , 2000, Molecular pharmacology.
[96] S. O. Smith,et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[97] E. Brown,et al. L-amino acid sensing by the extracellular Ca2+-sensing receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[98] L. Prézeau,et al. Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. , 2000, Molecular pharmacology.
[99] P B Hedlund,et al. Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. , 1999, Biochemical pharmacology.
[100] J. Ellis,et al. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.
[101] A. Christopoulos,et al. The assessment of antagonist potency under conditions of transient response kinetics. , 1999, European journal of pharmacology.
[102] R. Ranganathan,et al. Evolutionarily conserved pathways of energetic connectivity in protein families. , 1999, Science.
[103] R. Mobini,et al. Probing the immunological properties of the extracellular domains of the human beta(1)-adrenoceptor. , 1999, Journal of autoimmunity.
[104] R. Mishra,et al. Modulation of agonist stimulated adenylyl cyclase and GTPase activity by l-pro-l-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes , 1999, Neuroscience Letters.
[105] G. Wallukat,et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. , 1999, The Journal of clinical investigation.
[106] M. Maccoss,et al. Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor* , 1999, The Journal of Biological Chemistry.
[107] F. Gasparini,et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.
[108] G. Fillion,et al. Molecular, Cellular and Physiological Characteristics of 5‐HT‐Moduline, a Novel Endogenous Modulator of 5‐HT1B Receptor Subtype , 1998, Annals of the New York Academy of Sciences.
[109] A. Berra,et al. Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. , 1998, Current eye research.
[110] E. De Clercq,et al. Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.
[111] J. Garrett,et al. Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. , 1998, Molecular pharmacology.
[112] Hans H. Zingg,et al. Inhibition of oxytocin receptor function by direct binding of progesterone , 1998, Nature.
[113] M F Balandrin,et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[114] A. Christopoulos,et al. ALLOSTERIC INTERACTIONS AT MUSCARINIC CHOLINOCEPTORS , 1998, Clinical and experimental pharmacology & physiology.
[115] G. Wallukat,et al. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. , 1998, European journal of biochemistry.
[116] M. Neal,et al. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[117] G. Gimpl,et al. Cholesterol as modulator of receptor function. , 1997, Biochemistry.
[118] A. Christopoulos,et al. Application of an Allosteric Ternary Complex Model to the Technique of Pharmacological Resultant Analysis , 1997, The Journal of pharmacy and pharmacology.
[119] D. Sibley,et al. Zinc Allosterically Modulates Antagonist Binding to Cloned D1 and D2 Dopamine Receptors , 1997, Journal of neurochemistry.
[120] E. Borda,et al. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[121] E. Kostenis,et al. KOSTENIS AND MOHR REPLY : COMPOSITE ACTION OF ALLOSTERIC MODULATORS ON LIGAND BINDING , 1996 .
[122] S. Hoare,et al. Regulation of D2 dopamine receptors by amiloride and amiloride analogs. , 1996, Molecular pharmacology.
[123] R. Hen,et al. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. , 1996, Molecular pharmacology.
[124] S. Lazareno,et al. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. , 1995, Molecular pharmacology.
[125] A. Strosberg,et al. Characterization of Pharmacologically Active Anti‐Peptide Antibodies Directed Against the First and Second Extracellular Loops of the Serotonin 5‐HT1A Receptor , 1995, Journal of neurochemistry.
[126] S. Lazareno,et al. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.
[127] A. Christopoulos,et al. Assessment of the allosteric interactions of the bisquaternary heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide at M1 and M2 muscarine receptors. , 1994, Molecular pharmacology.
[128] M. Eck,et al. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. , 1994, Molecular pharmacology.
[129] A. Fryer,et al. Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. , 1992, The Journal of clinical investigation.
[130] J. Ellis,et al. Two allosteric modulators interact at a common site on cardiac muscarinic receptors. , 1992, Molecular pharmacology.
[131] D Rodbard,et al. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. , 1992, Molecular pharmacology.
[132] E. Borda,et al. Distribution of Antibodies against β-Adrenoceptors in the Course of Human Trypanosoma cruzi Infection , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[133] J. Fergus,et al. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.
[134] P. Portoghese. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. , 1989, Trends in pharmacological sciences.
[135] F. Ehlert,et al. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.
[136] F. Ehlert. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. , 1985, Molecular pharmacology.
[137] E. Borda,et al. A circulating IgG in Chagas' disease which binds to beta-adrenoceptors of myocardium and modulates their activity. , 1984, Clinical and experimental immunology.
[138] J. Changeux,et al. ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.
[139] J. Changeux,et al. Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.
[140] B. Katz,et al. A study of the ‘desensitization’ produced by acetylcholine at the motor end‐plate , 1957, The Journal of physiology.
[141] J. Wyman,et al. The problem of the heme interactions in hemoglobin and the basis of the bohr effect , 1951 .
[142] Christian Bohr,et al. Ueber einen in biologischer Beziehung wichtigen Einfluss, den die Kohlensäurespannung des Blutes auf dessen Sauerstoffbindung übt1 , 1904 .